Funding for this research was provided by:
AstraZeneca
Article History
First Online: 23 September 2019
Change Date: 5 November 2019
Change Type: Correction
Change Details: Page 5, Fig. 2 Key milestones in the development of budesonide.
Compliance with Ethical Standards
:
: This manuscript was supported with funding for medical writing assistance by AstraZeneca, in accordance with Good Publication Practice (GPP3) guidelines (ExternalRef removed).
: Donald Tashkin has been the recipient of research grant support and fees for speaking and serving as a scientific advisory board member for AstraZeneca, an advisory board member and speaker for Teva, an advisory board member for Innoviva, the recipient of research grant support and an advisory board member for Novartis and a speaker and advisory board member for Sunovion. Brian Lipworth has received support from AstraZeneca for attending ATS 2018 as well as consultancy payments. He has also received payments for speaking, consulting, or advisory boards with Chiesi, Novartis, Sandoz, Sanofi, Teva, Lupin, Genentech, Boehringer Ingelheim, Dr. Reddy’s, Cipla, Vectura and Glenmark. Support for unrestricted grants or multicentre trials has been received from AstraZeneca, Teva, Janssen and Chiesi. Equipment and educational support provided by GlaxoSmithKline. Ralph Brattsand is a former employee of Astra and AstraZeneca but today is without economic support from them. He was one of the key inventors of budesonide, and holds stocks with AstraZeneca.